---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-009321"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T18:09:42.602188+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biofrontera reports positive Phase 2b results for Ameluz PDT in moderate-to-severe acne; plans FDA meeting in Q3 2026

## Summary
- Phase 2b study: 3-hour Ameluz incubation achieved 57.97% reduction in inflammatory lesions vs 36.51% for vehicle.
- 25% of Ameluz patients met mIGA co-primary endpoint (clear/almost clear) vs 21.4% with vehicle.
- Safety profile consistent with prior PDT; most treatment-related AEs were mild-to-moderate burning and pruritus.
- 85.7% of 3-hour Ameluz patients would choose PDT again; 71.4% rated esthetic outcome good/very good.
- Company to present data to FDA in Q3 2026 to discuss next steps for acne vulgaris indication.

## SEC filing metadata
- accession: 0001493152-26-009321
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315226009321/0001493152-26-009321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315226009321/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-009321
- JSON: https://secwatch.observer/filing/0001493152-26-009321.json
- Plain text: https://secwatch.observer/filing/0001493152-26-009321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.